Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
Like
Facebook
Tweet
AIBDR 3.31-4.1
JAK Inhibitors: Efficacy and Safety
Saturday, April 1, 2023
12:15 PM – 12:30 PM
.
Speaker(s)
David T. Rubin, MD, FACG (he/him/his)
University of Chicago Medicine
Chicago, Illinois
Disclosure(s):
David T. Rubin, MD, FACG
: disclosed no relevant financial relationship with any ineligible company (commercial interest).
Learning Objectives:
Understand the need and benefit of novel small molecule therapy in IBD
Incorporate JAK inhibitors in the management of patients with IBD
Interpret the safety data for novel targeted small molecule therapies for patients with IBD